Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model

MM. Evers, J. Miniarikova, S. Juhas, A. Vallès, B. Bohuslavova, J. Juhasova, HK. Skalnikova, P. Vodicka, I. Valekova, C. Brouwers, B. Blits, J. Lubelski, H. Kovarova, Z. Ellederova, SJ. van Deventer, H. Petry, J. Motlik, P. Konstantinova,

. 2018 ; 26 (9) : 2163-2177. [pub] 20180625

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035126

Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Previously, we showed strong huntingtin reduction and prevention of neuronal dysfunction in HD rodents using an engineered microRNA targeting human huntingtin, delivered via adeno-associated virus (AAV) serotype 5 vector with a transgene encoding an engineered miRNA against HTT mRNA (AAV5-miHTT). One of the challenges of rodents as a model of neurodegenerative diseases is their relatively small brain, making successful translation to the HD patient difficult. This is particularly relevant for gene therapy approaches, where distribution achieved upon local administration into the parenchyma is likely dependent on brain size and structure. Here, we aimed to demonstrate the translation of huntingtin-lowering gene therapy to a large-animal brain. We investigated the feasibility, efficacy, and tolerability of one-time intracranial administration of AAV5-miHTT in the transgenic HD (tgHD) minipig model. We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression. Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT. The combination of widespread vector distribution and extensive huntingtin lowering observed with AAV5-miHTT supports the translation of a huntingtin-lowering gene therapy for HD from preclinical studies into the clinic.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035126
003      
CZ-PrNML
005      
20191015121511.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ymthe.2018.06.021 $2 doi
035    __
$a (PubMed)30007561
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Evers, Melvin M $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands. Electronic address: m.evers@uniqure.com.
245    10
$a AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model / $c MM. Evers, J. Miniarikova, S. Juhas, A. Vallès, B. Bohuslavova, J. Juhasova, HK. Skalnikova, P. Vodicka, I. Valekova, C. Brouwers, B. Blits, J. Lubelski, H. Kovarova, Z. Ellederova, SJ. van Deventer, H. Petry, J. Motlik, P. Konstantinova,
520    9_
$a Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Previously, we showed strong huntingtin reduction and prevention of neuronal dysfunction in HD rodents using an engineered microRNA targeting human huntingtin, delivered via adeno-associated virus (AAV) serotype 5 vector with a transgene encoding an engineered miRNA against HTT mRNA (AAV5-miHTT). One of the challenges of rodents as a model of neurodegenerative diseases is their relatively small brain, making successful translation to the HD patient difficult. This is particularly relevant for gene therapy approaches, where distribution achieved upon local administration into the parenchyma is likely dependent on brain size and structure. Here, we aimed to demonstrate the translation of huntingtin-lowering gene therapy to a large-animal brain. We investigated the feasibility, efficacy, and tolerability of one-time intracranial administration of AAV5-miHTT in the transgenic HD (tgHD) minipig model. We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression. Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT. The combination of widespread vector distribution and extensive huntingtin lowering observed with AAV5-miHTT supports the translation of a huntingtin-lowering gene therapy for HD from preclinical studies into the clinic.
650    _2
$a zvířata $7 D000818
650    _2
$a geneticky modifikovaná zvířata $7 D030801
650    _2
$a Dependovirus $x genetika $7 D000229
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a genetická terapie $x metody $7 D015316
650    _2
$a genetické vektory $x genetika $7 D005822
650    _2
$a lidé $7 D006801
650    _2
$a protein huntingtin $x genetika $x metabolismus $7 D000071058
650    _2
$a Huntingtonova nemoc $x genetika $x metabolismus $x terapie $7 D006816
650    _2
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    _2
$a prasata $7 D013552
650    _2
$a miniaturní prasata $7 D013556
650    _2
$a expanze trinukleotidových repetic $x genetika $7 D019680
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Miniarikova, Jana $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Juhas, Stefan $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Vallès, Astrid $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Bohuslavova, Bozena $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Juhasova, Jana $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Skalnikova, Helena Kupcova $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Vodicka, Petr $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Valekova, Ivona $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Brouwers, Cynthia $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Blits, Bas $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Lubelski, Jacek $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Kovarova, Hana $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Ellederova, Zdenka $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a van Deventer, Sander J $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Petry, Harald $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
700    1_
$a Motlik, Jan $u Institute of Animal Physiology and Genetics, Libechov, Czech Republic.
700    1_
$a Konstantinova, Pavlina $u Department of Research & Development, uniQure biopharma B.V., Amsterdam, the Netherlands.
773    0_
$w MED00189556 $t Molecular therapy : the journal of the American Society of Gene Therapy $x 1525-0024 $g Roč. 26, č. 9 (2018), s. 2163-2177
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30007561 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015121936 $b ABA008
999    __
$a ok $b bmc $g 1451786 $s 1073676
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 26 $c 9 $d 2163-2177 $e 20180625 $i 1525-0024 $m Molecular therapy $n Mol Ther $x MED00189556
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options